 |
|
|||||||||||||||||||||||||||||
| [发表评论] [本类其他产品] [本类其他供应商] [收藏] | ||||||||||||||||||||||||||||||
| 销售商： 上海基锘威生物科技有限公司 | 查看该公司所有产品 >> |
Design of the CT26-Pd‑l1 Knockout
The CT26.WT cell line was derived and subcloned from Balb/c murine colon carcinoma and forms tumors at high frequency when inoculated subcutaneously. We generated CT26-Pd-l1 Knockout clonal cell lines invalidated for murine Pd-l1 (Cd274).
Applications in immuno-oncologyThe CT26-Pd-l1 Knockout clones can be used for target validation and mechanistic studies.
Humanized CT26-hPD-L1 cell line:
Use our humanized CT26-hPD-L1 cell line for in vivo tumor growth assays in syngeneic models.
CT26-Pd-l1 Knockout features- Invalidated for murine Pd-l1
- Form tumors upon subcutaneous injection in fully immunocompetent mice
Expression analysis by FACS. mPd-l1 expression in CT26‑Pd‑l1 Knockout (KO) clone and parental cell line.
Wild-type Balb/c mice were injected (s.c.) with 1x105 CT26.WT (A) or CT26-Pd-l1 KO (B) cells. Tumor growth was measured every 2 to 3 days. Tumor size (mm3) = (width2 x length)/2. 8 mice (mixed gender) were injected per group, with 8 mice developing tumors for CT26.WT and CT26-Pd-l1 KO.
更多详细数据请联系我们：联系我们 - 基锘威 - genOway (my3w.com)
